JP2020517645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517645A5 JP2020517645A5 JP2019556913A JP2019556913A JP2020517645A5 JP 2020517645 A5 JP2020517645 A5 JP 2020517645A5 JP 2019556913 A JP2019556913 A JP 2019556913A JP 2019556913 A JP2019556913 A JP 2019556913A JP 2020517645 A5 JP2020517645 A5 JP 2020517645A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oligonucleotide
- composition according
- bond
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 34
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 14
- 150000003904 phospholipids Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000007935 neutral effect Effects 0.000 claims 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 4
- 150000004713 phosphodiesters Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 239000002777 nucleoside Substances 0.000 claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487425P | 2017-04-19 | 2017-04-19 | |
| US62/487,425 | 2017-04-19 | ||
| PCT/US2018/028308 WO2018195281A1 (en) | 2017-04-19 | 2018-04-19 | P-ethoxy nucleic acids for igf-1r inhibition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517645A JP2020517645A (ja) | 2020-06-18 |
| JP2020517645A5 true JP2020517645A5 (enExample) | 2021-05-27 |
Family
ID=63856055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556913A Pending JP2020517645A (ja) | 2017-04-19 | 2018-04-19 | Ｉｇｆ−１ｒ阻害のためのｐ−エトキシ核酸 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200038429A1 (enExample) |
| EP (1) | EP3628003A4 (enExample) |
| JP (1) | JP2020517645A (enExample) |
| KR (1) | KR20200021453A (enExample) |
| CN (1) | CN111447922A (enExample) |
| AU (1) | AU2018254485B2 (enExample) |
| CA (1) | CA3060090A1 (enExample) |
| MX (1) | MX2019012493A (enExample) |
| WO (1) | WO2018195281A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206942B2 (en) | 2015-04-10 | 2019-02-19 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes |
| KR102755601B1 (ko) | 2015-10-14 | 2025-01-17 | 바이오-패쓰 홀딩스 인크. | 리포좀 제제를 위한 p-에톡시 핵산 |
| US10927379B2 (en) | 2016-09-16 | 2021-02-23 | Bio-Path Holdings, Inc. | Combination therapy with liposomal antisense oligonucleotides |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
| US12234457B2 (en) | 2017-04-19 | 2025-02-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for BCL2 inhibition |
| JP2022512894A (ja) * | 2018-11-02 | 2022-02-07 | トーマス・ジェファーソン・ユニバーシティ | アンチセンスを使用した乳癌治療用の方法および組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
| US6015886A (en) * | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US7704962B1 (en) * | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| US20030180789A1 (en) * | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
| AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| US10806095B2 (en) | 2014-07-17 | 2020-10-20 | Signify Holding B.V. | Horticultural lighting apparatus |
| US10206942B2 (en) * | 2015-04-10 | 2019-02-19 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes |
| KR102755601B1 (ko) | 2015-10-14 | 2025-01-17 | 바이오-패쓰 홀딩스 인크. | 리포좀 제제를 위한 p-에톡시 핵산 |
-
2018
- 2018-04-19 JP JP2019556913A patent/JP2020517645A/ja active Pending
- 2018-04-19 WO PCT/US2018/028308 patent/WO2018195281A1/en not_active Ceased
- 2018-04-19 CA CA3060090A patent/CA3060090A1/en active Pending
- 2018-04-19 CN CN201880036079.XA patent/CN111447922A/zh active Pending
- 2018-04-19 KR KR1020197034170A patent/KR20200021453A/ko not_active Ceased
- 2018-04-19 MX MX2019012493A patent/MX2019012493A/es unknown
- 2018-04-19 EP EP18788289.9A patent/EP3628003A4/en not_active Withdrawn
- 2018-04-19 AU AU2018254485A patent/AU2018254485B2/en active Active
- 2018-04-19 US US16/606,377 patent/US20200038429A1/en not_active Abandoned
-
2021
- 2021-11-18 US US17/530,051 patent/US12472199B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517645A5 (enExample) | ||
| Zhang et al. | A comprehensive review of small interfering RNAs (siRNAs): mechanism, therapeutic targets, and delivery strategies for cancer therapy | |
| Liu et al. | Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles | |
| Tran et al. | Exosomes and nanoengineering: a match made for precision therapeutics | |
| Gissot et al. | Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids | |
| Deng et al. | Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer | |
| Couvreur et al. | Nanotechnologies for drug delivery: Application to cancer and autoimmune diseases | |
| Vandghanooni et al. | Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective | |
| ES2743188T3 (es) | Péptidos y nanopartículas para el suministro intracelular de moléculas | |
| JP2020517632A5 (enExample) | ||
| JP5906327B2 (ja) | 磁性ナノ粒子−ＳＡＭｉＲＮＡ複合体およびその製造方法 | |
| CN110072530A (zh) | 4′-磷酸酯类似物和包含其的寡核苷酸 | |
| CN112107693A (zh) | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 | |
| CN105051205B (zh) | 鉴定生物标记物、治疗靶点或治疗试剂的高通量筛选方法 | |
| Nam et al. | Size-controlled synthesis of polymerized DNA nanoparticles for targeted anticancer drug delivery | |
| IL269608B2 (en) | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease | |
| Gopinath et al. | Cell-targeting aptamers act as intracellular delivery vehicles | |
| JP2018534361A5 (enExample) | ||
| CN102458379B (zh) | 基于官能两亲分子或大分子的具有多隔室的配制剂 | |
| Senanayake et al. | Novel anticancer polymeric conjugates of activated nucleoside analogues | |
| JP2020517646A5 (enExample) | ||
| Tan et al. | Designer tridentate mucin 1 aptamer for targeted drug delivery | |
| CN105779458B (zh) | 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物 | |
| JP2024508119A (ja) | Ｒｎａｉコンジュゲートおよびその使用 | |
| TWI589307B (zh) | Novel manufacturing method for local administration of lipid complex and antitumor agent using the lipid complex |